|Mr. Umang Vohra||MD, Global CEO & Exec. Director||229M||N/A||1971|
|Ms. Samina Hamied||Exec. Vice-Chairperson||91.1M||N/A||1976|
|Dr. Raju Sunil Mistry M.A., Ph.D.||Pres & Global Chief People Officer||N/A||N/A||1965|
|Mr. Pradeep Bhadauria||Pres & Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Ashish Adukia||Global Chief Financial Officer||N/A||N/A||N/A|
|Mr. Dinesh Ramniranjan Jain||Sr. VP & Head of Corp. Fin.||N/A||N/A||N/A|
|Ms. Geena V. Malhotra||Global Chief Technology Officer||N/A||N/A||N/A|
|Mr. Naveen Bansal||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Gautam Rohidekar||Chief Legal Officer||N/A||N/A||N/A|
|Mr. Rajendra Kumar Chopra||Compliance Officer & Company Sec.||N/A||N/A||N/A|
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
Cipla Limited’s ISS governance QualityScore as of 1 November 2022 is 3. The pillar scores are Audit: 6; Board: 1; Shareholder rights: 1; Compensation: 9.